La prise en charge de votre asthme est plus importante que jamais. Par conséquent, nous aimerions vous inviter à vous joindre à Stéphane Côté qui discutera de ce qui suit :
Meilleure façon de prendre en charge votre asthme (ou celui de votre enfant)
Comment maîtriser l’asthme
Utilisation de médicaments inhalés et rôle des chambres d’inhalation
Manage asthma during wildfires by monitoring air quality, indoor cleanliness, limiting outdoor exposure, wearing masks, consulting healthcare providers, and optimizing medication with AeroChamber VHC* and AeroChamber 2Go*.
Manage asthma during wildfires by monitoring air quality, indoor cleanliness, limiting outdoor exposure, wearing masks, consulting healthcare providers, and optimizing medication with AeroChamber VHC* and AeroChamber 2Go*.
From a UK perspective, BUD/F delivered via an MDI + VHC offers an economic benefit for the treatment of patients with mild asthma. Further analysis is required to determine if there would be any quality-adjusted life-year (QALY) effects based on the chosen intervention.
The prototype AeroChamber2go* spacer device was preferred by patients compared to the A2A† spacer and provides a good option for patients currently using the Metered Dose Inhaler without a spacer while on-the-go.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
Medication delivery can vary significantly depending on the pMDI/spacer system which will have implications on the carbon footprint. In this case, the use of the AeroChamber Plus* Flow-Vu* spacer could potentially reduce the carbon footprint by up to five-fold compared to other spacers.
The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.
As a medical device manufacturer, we are committed to minimizing any disruption to the supply of our products to our customers globally, during this unprecedented time with the outbreak of COVID-19.
